EFS revealed that IL-6, NGAL, and resistin are suitable markers for discrimination between AECOPD and CAP, and the discrimination was still possible with these selected features even when the CAP patient additionally suffers from COPD. This evidence concerns the gene LCN2 and chronic obstructive pulmonary disease.